Diagnostic Antibodies for In Vivo Visualization of Tumor Cells

Molecular imaging of cancer has the potential to facilitate early detection and to provide a more detailed assessment of disease and tumor margin. Molecular imaging probes have been heralded by the FDA Critical Path Initiative as tools to increase the speed and cost-effectiveness of clinical trials for cancer therapies. However, imaging probes currently in use in the clinic are limited by a lack of specificity and/or sensitivity or are limited to a small subset of cancers. Therefore, new molecular imaging probes with more broad applications to cancer are needed. Kristin Agopian kristin.agopian@ucsf.edu 415-340-2619